Leap Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
47 Thorndike St Ste B1-1, Cambridge, Mas...Phone Number
(617) 714-0360Website
www.leaptx.comRevenue
$11.4 MillionStock Symbol
LPTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leaps most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.Explore more
Leap Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Leap Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Leap Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Leap Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Leap Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Leap Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Leap Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Leap Therapeutics has new funding data
Product Launch: Get notified when Leap Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Leap Therapeutics
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Leap Therapeutics
Find 3 more new buyers
Compare Similar Companies to Leap Therapeutics
Compare insights from companies similar to Leap Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Leap Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Leap Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Leap Therapeutics.
Leap Therapeutics financials insights
Gather financial insights about Leap Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$51.8M
2021
Stock Offering
$104M
2025
Stock/Share Issuance
$58.8M
Leap Therapeutics Tech Stack
A closer look at the technologies used by Leap Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Funding
Funding
Project
Leap Therapeutics has proposed to ratify the appointment of Eisner Ampere LLP as its independent auditors for the year ending December 31, 2025.
Audit, Finance, Financial Operations
Layoffs
Layoffs
Person-Based
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Leap Therapeutics
Sign Up For FreeTo access detailed company insights
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leaps most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoc... Read More
